Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO* study

AIDS

Volumn 14, Issue 1, 2000, Pages 37-49

  Saint Marc, Thierry ^a   Partisani, Maria ^c   Poizot Martin, Isabelle ^e   Rouviere, Olivier ^a,b   Bruno, F ^d   Avellaneda, R ^a   Lang, Jean Marie ^e   Gastaut, Jean Albert ^e   Touraine, Jean Louis ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d Stat'Aids   (France)

^e Hop Edouard Herriot Place d'A ^*

Author keywords

Antiretroviral therapy; HIV; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; C PEPTIDE; DIDANOSINE; GLUCOSE; INDINAVIR; INSULIN; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BIOENERGY; BODY COMPOSITION; BODY FAT; CALORIC INTAKE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIVARIATE ANALYSIS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SKINFOLD THICKNESS; SUBCUTANEOUS FAT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADIPOSE TISSUE; ADULT; ANIMALS; ANTI-HIV AGENTS; BLOOD GLUCOSE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; INSULIN; LIPID METABOLISM; LIPIDS; LIPODYSTROPHY; MALE; MULTIVARIATE ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TOMOGRAPHY, X-RAY COMPUTED; VIRAL LOAD;

EID: 0012570692     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001070-00005     Document Type: Article

References (31)

1. 1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter of less. N Engl J Med 1997, 337:725-733.
2. 2. Carpenter CQJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the international AIDS society-USA panel. JAMA 1997, 277:1962-1969.
3. 3. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Buffalo hump in HIV-infected patients on antiretroviral therapy. 5th Conference on Retroviruses and Opportunistic Infections. Chicago-Illinois 1998 [abstract 409].
4. 4. Ruane PJ. Atypical accumulation of fatty tissue. 37th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Toronto 1997, 1:185.
5. 5. Miller K, Jones E, Yanovsky J, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
6. 6. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997, 350:1596.
7. 7. Carr A., Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
8. 8. Kotler DP, Rosenbaum K, Wang J, Pierson R. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr 1999, 20:228-237.
9. 9. Crunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinal Metab 1992, 74:1045-1052.
10. 10. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance, Lancet 1998, 351:1881-1883.
11. 11. Saint-Marc T, Poizot-Martin I, Partisani M, Fabre J, Touraine JL. A syndrome of lipodystrophy in patients receiving a stable nucleoside-analogue therapy. 6th conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 (abstract 653].
12. 12. Gervasoni C, Ridolfo AL, Trifiro C, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13:465-471.
13. 13. Polo R, Verdejo J, Gomez Cano M, et al. Lipodystrophy related to NRTI inhibitors in HAART therapy. 3rd Conference on Nutrition and HIV Infection. Cannes, April 1999 [abstract P10].
14. 14. Pettit R, Muurahainen N, Falutz J, et al. HIV-related truncal obesity: a comparison of physician and patient diagnoses in the SALSA (Self-Ascertained Lipodystrophy Syndrome Assessment) questionnaire. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 1999 [abstract 651].
15. 15. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis and prediction of HIV protease inhibitor (Pl)-induced lipodystrophy and impaired glucose tolerance. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 1999 [abstract 641].
16. 16. Romeu J, Bonjoch A, Arno A, et al. Lipodystrophy index by anthropometric parameters (LIAP): an approach to the diagnosis of lipodystrophy by measurable parameters in patients taking protease inhibitors. 6th Conference on Retroviruses and Opportunistic Infection, Chicago, January 1999 [abstract 652].
17. 17. Centers for Disease Control. 1993 Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1992, 41 (RR-17):1-19.
18. 18. Boulier A, Fricker J, Thomasset AL, et al. Fat-free mass estimation by the two-electrode impedance method. Am J Clin Nutr 1990, 52:581-585.
19. 19. Durnin JCVA, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974, 37:77-97.
20. 20. Enzi C, Gasparo M, Biondetti PR, Fiore D, Semisa M, Zurlo F. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr 1986, 44:739-746
21. 21. World Health Organization. Diabetes mellitus: report of a WHO study group. World Health Organ Tech Rep Ser 1985, 727:9-17.
22. 22. Intelligent Software Engineering. FoodPerfect. Nutritional analysis software. Victoria: Intelligent Software Engineering.
23. 23. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998, 12:F37-F39.
24. 24. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside-analogue (NRTI) therapy. AIDS 1999, 13:1659-1667.
25. 25. Saint-Marc T, Touraine JL The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999, 13:2188-2189.
26. 26. Kirk O, Mocroft A, Katzenstein TL, et al. Changes in use of antiretroviral therapy in regions of Europe over time. AIDS 1998, 12:2031-2039.
27. 27. Charakhanian S, Salhi Y, Nguyen TH, et al. Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 1999 [abstract 642).
28. 28. Hommes MJT, Romijn JA, Endert E, Karel J, Schattenkerk ME, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991, 40,6:651-656
29. 29. Walli K, Michl GM, Segerer S, et al. Dyslipidemia and insulin resistance in HIV-infected patients treated with reverse transcriptase inhibitors alone and in combination with protease inhibitors. 6th Conference on Retroviruses and Opportunistic Infection, Chicago, January 1999 [abstract 645].
30. 30. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller JVD. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999, 13:735-737.
31. 31. Carr A, Thorisdottir A, Samaras K, Kaufmann GR, Chisholm DJ, Cooper DA. Reversibility of protease inhibitor (Pl) lipodystrophy syndrome on stopping Pls or switching to nelfinavir. 6th Conference on Retroviruses and Opportunistic Infection, Chicago, January 1999 [abstract 668].